Merck KGaA Builds Plant in Switzerland

Merck KGaA says it will build a plant near Geneva to manufacture the company’s Erbitux monoclonal antibody cancer treatment. The announcement was made shortly after Merck KGaA completed the acquisition of a majority stake in biotechnology firm Serono (Geneva) and created a new division, Merck Serono (CW, Jan. 17, p. 23). Merck KGaA had previously planned to build the Erbitux plant at its Darmstadt, Germany...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers